Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117903 | 0.92 | TGM2 (0.41) | ABCB1KLK7SYKMEN1KMT2A | |
| SCHEMBL13448819 | 0.88 | ABCB1 (0.42) | ABCB1KLK7TACR1SYKSSTR2 | |
| SCHEMBL2440589 | 0.88 | ABCB1 (0.42) | ABCB1KLK7TACR1SYKSSTR2 | |
| SCHEMBL2437013 | 0.88 | KLK7 (0.40) | ABCB1KLK7TACR1KLK5SYK | |
| SCHEMBL2442750 | 0.84 | SSTR2 (0.37) | SSTR2MEN1KMT2A | |
| SCHEMBL12299472 | 0.84 | SSTR2 (0.37) | SSTR2MEN1KMT2A | |
| SCHEMBL2442154 | 0.82 | TGM2 (0.41) | ABCB1KLK7KLK5SYK | |
| SCHEMBL12299669 | 0.82 | TGM2 (0.41) | ABCB1KLK7KLK5SYK | |
| SCHEMBL2436780 | 0.82 | TGM2 (0.41) | ABCB1KLK7KLK5SYK | |
| SCHEMBL12299704 | 0.82 | TGM2 (0.41) | ABCB1KLK7KLK5SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | ABCB1 393/4885KLK7 2479/4885TACR1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.